62.70 -0.10 (-0.16%)
After hours: 6:43PM EDT
|Bid||62.55 x 900|
|Ask||62.70 x 1800|
|Day's Range||62.20 - 63.19|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||15.06|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||2.52 (3.88%)|
|1y Target Est||81.35|
Per the conditions of a $2 million loan from the state, Kite will employ a minimum of 352 people at the site and create an additional 72 jobs elsewhere in the state by December 2025.
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
Kite, a Gilead Company , today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T therapies, including Yescarta® , Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor ...
The U.S. Centers for Medicare and Medicaid Services will slightly increase coverage for expensive CAR-T cell therapies administered at certain large hospitals, and is considering other ways to pay more for the cancer treatments, the agency said on Tuesday. Both Gilead Sciences Inc's Yescarta therapy and Novartis AG's Kymriah have U.S. prices for advanced lymphoma patients of $373,000. Novartis did not immediately respond to a request for comment.
While gurus hold positions in these companies, the share price and returns continue to fall. The share price of $63 is 20.93% below its 52-week high and 4.36% above its 52-week low. The return on equity of 25.50% and return on assets of 8.29% are outperforming 79% of companies in the Drug Manufacturers - Major industry.
The vast majority of the time in a wishy-washy market environment like the one we're in now, "buying the dips and selling the rips" is an appropriate strategy. Traders can count on a reversal when a rally or meltdown becomes overextended.In some cases, though, a sharp stumble isn't necessarily a buying opportunity. Rather, it's a glimpse at the shape of things to come, with investors only beginning to file out of an equity.With that as the backdrop, here's a closer look at 10 oversold stocks to sell rather than scoop up at their currently depressed prices. While investors should remain on guard for rebounds inspired by bargain-hunters expecting the reversals we'd normally see in such situations, in all of these cases we've seen a handful of red flags suggesting things could get worse before that get better.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 High-Yielding Dividend Stocks That Won't Wilt In no particular order… Stocks to Sell: J B Hunt Transport Services (JBHT)It wasn't a disastrous quarter, but last quarter's numbers from J B Hunt Transport Services (NASDAQ:JBHT) were far from being impressive. More than that, they may be a microcosm of a bigger headwind that's now blowing.One issue, ironically, is that the economy is so strong and jobs are so plentiful, trucking companies like J B Hunt are struggling to find and keep drivers. Then there's slowing demand for intermodal transportation, mostly crimped by trade friction between the U.S. and China. Earnings of $1.09 per share fell short of the $1.26 analysts were expecting.That lackluster future is still being priced into the chart. Though down by nearly one-fourth since June's peak, JBHT shares have yet to slide back to a long-term support line, currently at $83. The current trend pushing shares that direction has plenty of momentum too. Mattel (MAT)To its credit, toymaker Mattel (NASDAQ:MAT) has done its best to adapt to an electronic, digital world. In January, Chief Technology Officer Sven Gerjets demonstrated the company's deep understanding that the future is 'phygital' … the melding of traditional physical toys with computerized technology. The company is thinking aggressively about media tie-ins too, reportedly planning a live-action film featuring Mattel's beloved Barbie doll. * 7 Tech Stocks With Too Much Risk, Not Enough Upside For whatever reason, though, nothing really seems to be clicking for the once-iconic company. Though MAT stock looked like it would finally work out a reversal after December's hard landing, the selling that got started back in 2014 has been renewed this month. The stock is down nearly 70% from the peak made five years ago, and once again within easy reach of multi-year lows. Gilead Sciences (GILD)When Gilead Sciences (NASDAQ:GILD) shares tumbled in 2016, investors largely knew why. An amazing run in 2013 and 2014 stemming from sky-high prices of its hepatitis C drugs Harvoni and Sovaldi -- which were effectively 'cures' -- were about to be challenged by cheaper competitors as well as social outrage over their needlessly high price tag.By early 2017, though, investors figured the worst had been priced in and assumed Gilead would properly regroup for the road ahead.That hasn't turned out to be the case though. GILD stock has been steadily trending lower since its early 2018 high, and if shares break below a technical floor right around $60, this oversold name will most definitely become one of a handful of stocks to sell.In short, Gilead Sciences simply isn't holding up to its competition. Nordstrom (JWN)It's sometimes difficult to tell given the number of store closing we're still seeing, but the so-called retail apocalypse is abating. That's a big reason Nordstrom (NYSE:JWN) rallied in 2018. For a short while, it appeared as if the upper-end chain of stores would emerge from the industry-wide meltdown as healthy as it has ever been.It's now clear, however, that while not as brutal, the retail apocalypse is still underway, and still plaguing some slivers of the business more than others. Last quarter's total top line of $4.48 billion was not only down from the year-ago tally of $4.7 billion, it also fell short of the $4.61 billion analysts were expecting. Same-store sales at its full-priced venues was a scant 0.1%. * 5 Dividend Stocks Perfect for Retirees JWN is already one of several oversold stocks in the sector. But, if it breaks below the support line that tagged the 2016 and 2017 lows, it will earn a spot on a short list of stocks to sell. Wells Fargo (WFC)Wells Fargo (NYSE:WFC), to be clear, is mostly suffering from self-inflicted wounds. The 2016 account-opening scandal led to backlash from multiple directions ever since.The public -- consumers -- was at least willing to forgive if not outright forget. A surprising string of quarterly results carried WFC stock to record highs by early 2018.That's when regulators really started to sink their teeth into the company's hide though. Among other things, the mega bank in August was charged more than $2 billion for making improper mortgage loans. The clincher, however, is the fact the Federal Reserve has capped the company's permitted assets it can leave on the books, essentially capping earnings growth. The company doesn't believe that growth ban will be lifted anytime this year.With little to look forward to, WFC shares are in a well-developed downtrend that probably won't find a firm floor until it reaches the $41 area. L Brands (LB)L Brands (NYSE:LB) shares are down a stunning 69% from their late-2015 peak, and that downtrend is still going strong. The stock is only a few pennies away from new multiyear lows, and given its bearish momentum, odds are good it will once again slide deeper into the red.L Brands, of course, is the parent company of Victoria's Secret and Bath & Body Works … two powerhouses in the heyday of mall shopping, but two venues that are struggling to connect with consumers in a digital world where shoppers splurge in different ways. While revenue growth remains steady, quarterly operating income has been reliably shrinking since early 2016 as L Brands has to spend more and more to keep patrons coming to its stores. And even then, things are tough. Fourth-quarter same-store sales excluding e-commerce spending was down 1%, extending a concerning streak of backpedaling. * 10 S&P 500 Stocks to Weather the Earnings Storm In that light, the stock's long-term downtrend makes sense. AbbVie (ABBV)AbbVie (NYSE:ABBV) was a heroic performer in 2017, rallying from $57 to an early 2018 peak near $117, mostly driven by impressive sales growth from Humira as well as Imbruvica. The former's revenue was up 14.4% that year, and the latter's grew more than 40%.The big run-up only set up a sizable fall though, spurred not by slowing revenue growth, but an impending and inevitable threat to its Humira franchise.The company has been maneuvering for years to maintain the patent on its flagship drug Humira, to be clear, which generated nearly $20 billion in revenue last year. But, time is ultimately working against AbbVie. Earlier this month six separate lawsuits were filed against the pharmaceutical giant, each making the same basic claim … that biosimilars of Humira should already be allowed in the United States.Investors appear to know the company won't be able to fend off these legal arguments for much longer. Nektar Therapeutics (NKTR)In late 2017, the Nektar Therapeutics (NASDAQ:NKTR) rally was unstoppable. Eli Lilly (NYSE:LLY) had made an upfront cash payment to the company in exchange for development and participation rights in T-cell booster NKTR-358, and at the same time posted big-time third quarter revenue growth.As is so often the case in the biopharma arena, though, excited investors overestimated what was to come, and how quickly that would take shape. In June of last year a trial of cancer therapy NKTR-214 led to lackluster results, and in February the company once again reported just so-so outcomes with the same drug in use as a therapy for a different form of cancer. * 7 Stocks to Buy for Spring Season Growth Nektar Therapeutics shares have fallen more than 70% since their early 2018 high, and are pennies away from breaking below an established support level of right around $30. HP (HPQ)After a brief stumble in 2015 when it split with the enterprise-oriented half of the company Hewlett Packard Enterprise (NYSE:HPE) to focus on consumer-level computers and printers, HP (NYSE:HPQ) started what would turn into a solid, multiyear advance. The early-2016 low near $8 gave way to a move to 2018's peak near $27, partially driven by steadying PC sales, and partially prompted by an improving economy.That 2018 peak, however, has also become a perfect pivot. Since then HPQ shares have logged a lower major low and lower major high, and as of this week appear to be aiming at a new 52-week low. Traders aren't buying on the dip -- at least not in earnest -- now that the bullish trend lines of yesteryear have been snapped. Davita (DVA)Finally, add Davita (NYSE:DVA) to your list of oversold stocks to sell rather than buy. Though down 36% from its early 2018 high, there's still room and reason for it to continue sinking.It may not be a household name, but it may ring a bell all the same. Davita is a chain of kidney care and dialysis centers that for years had been one of Warren Buffett's favorite stock picks. The company was a reliable cash generator … right up Buffett's alley.Buffett, through Berkshire Hathaway, still owns a big stake in Davita, but arguably wishes he didn't. Operating income turned unpredictable beginning in 2012, and in 2017 began to shrink more often than grow. That headwind has been reflected in the stock's price from the point in time it started to blow. * 10 High-Yielding Dividend Stocks That Won't Wilt Buffett and Berkshire appear to still be committed to the trade. Given the uncertain future the country's healthcare system faces though, on top of the trouble the company was facing even before such questions surfaced, there's no end in sight for the stock's net-bearishness.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post 10 Oversold Stocks to Run From appeared first on InvestorPlace.
With the market stagnating near these upper levels, but not showing a willingness to pullback in any meaningful way, trade setups are becoming harder to find. That's not necessarily a bad thing, as it gives traders a chance to wait for more opportune trades. Let's see which top stock trades are presenting themselves now. Top Stock Trades for Tomorrow 1: TeslaTesla (NASDAQ:TSLA) had its Autonomy Investor Day on Monday afternoon. Enthusiasts are excited by what the company has to show off and doubters are eager to pounce on anything that suggests Tesla has no edge.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhat does it mean for the stock price though?Shares were lower by about 3.5% heading into the event and near long-time support. This seemingly sets up the stock up for a bounce, particularly with earnings just around the corner on April 24th. However, some concerns are mounting on the technical front. * 3 Stocks on Shaky Ground For starters, Tesla hasn't been able to break over its downtrend (blue line) on a closing basis for almost three months now. Further, the 200-week moving average -- which has been support many times over the past few years -- is not giving TSLA the bounce it needs. In fact, TSLA stock has closed below this mark four of the last five weeks, assuming we skip this week's candle.Needless to say, Tesla is sitting at an important juncture. Below $250 and the situation could go from bad to worse in a hurry. Back over $280+ though and the bulls will have momentum back on their side.Be aware of two situations, too: either a dump before earnings or a strong rally. Either could end up being a head fake. Top Stock Trades for Tomorrow 2: Gilead SciencesDown about 2% on the day and Gilead Sciences (NASDAQ:GILD) isn't looking all that good. Keep this one simple.It's flirting with vital support between $60 and $62 with downtrend resistance (blue line) squeezing it lower. Below $60 and GILD is in no man's land. Above downtrend resistance and GILD will have to contend with $70. Top Stock Trades for Tomorrow 3: TwitterTwitter (NYSE:TWTR) will report earnings on Tuesday before the open, as the stock has been trading in a very tight range for the month. For now, it's holding above the 20-day and 50-day moving averages and just below stiff resistance at $36.On earnings, look for a close over $36 to signal a potential breakout to higher prices. On a pullback, see that uptrend support holds. If it does, the more quickly it can reclaim the 20-day and 50-day moving averages, the better.If uptrend support doesn't hold, $30 is in the cards and possibly $28 if that doesn't hold. Let's not get over our skis though. I want to see how TWTR trades after earnings first. Top Stock Trades for Tomorrow 4: The Trade DeskWe have been flagging The Trade Desk (NASDAQ:TTD) a lot over the past few trading sessions, either looking for a breakout or a breakdown. As it so happens, a breakout is we're getting and now investors are trying to position themselves in the name.If you missed the entry trigger over downtrend resistance, chasing may not be worth the risk. Current longs should watch $215 to see if TTD can push through. If it can, a new breakout could be underway and more upside could exist, which gives an opportunity to investors looking to get on board.Notice that TTD is not overbought according to the RSI, while its momentum via the MACD is just swinging in bulls' favor, (both measures shown via blue circles).Should we get a pullback to the backside of prior downtrend resistance (black line), it could be a buying opportunity if it holds as support. Top Stock Trades for Tomorrow 5: Realty IncomeWe flagged this one about a week ago as the REITs started to come under pressure. I wasn't sure if it was a premature reaction or a savvy move, but I followed my gut and exited my REITs as this action developed.At the time, we said look for $68 to act as support in Realty Income (NYSE:O). After strong selling, it was support -- for one day. On Monday, O cratered below this mark as the stock is quickly down 9% from its highs less than a month ago. The 20-day moving average is also rolling below the 50-day moving average, which isn't a deal-breaker for bulls, but certainly isn't a great development.So what now? * 7 Tech Stocks With Too Much Risk, Not Enough Upside Almost 10% off its highs and it's hard to be a seller at this point. But I don't know that it's fallen far enough to buy yet. One strategy? Let it shake out. A rally back up to $68 or to the 20-day/50-day that's met by sellers could be an opportunity on the short side or for bulls to unload some of their holding. If it keeps going lower without a bounce, look for an eventual buying opportunity.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post 5 Top Stock Trades for Tuesday: TSLA, TWTR, TTD, O appeared first on InvestorPlace.
Gilead Sciences Inc., CVS Health Corp, Macerich Co. and OPKO Health Inc. have declined to their respective three-year lows
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
Gilead Sciences, Inc. (GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2019 and provide a business update.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would wait for Arista Networks Inc (NYSE: ANET ) to come down before buying the stock. Cramer likes NVIDIA (NASDAQ: NVDA ). He loves ...
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
Gilead Sciences announced a collaboration Tuesday to use machine learning to seek new treatment options for a progressive liver disease. It will pay Insitro $15 million upfront for the deal.
At first glance, shares of Amgen (NASDAQ:AMGN) look quite volatile. Upon further inspection, though, the six-month range in AMGN stock is actually pretty tight -- and it's been getting even tighter, as the stock has spent much of 2019 gathering in tightening coil. This sets up for a potentially large move. This move can happen in either direction, with bulls hoping Amgen stock resolves higher. * 7 Stocks That Can Outperform for Years Source: Richard Masoner via Flickr There are a lot of considerations when it comes to pulling the trigger on a name like Amgen. It's not just the technicals, but also the dividend, its valuation and growth profile. Let's take a closer look, first with the charts. Trading AMGN Stock Click to EnlargeAMGN is not the kind of stock that traders are normally drawn to. That's more for the names like Advanced Micro Devices (NADSAQ:AMD), Tesla (NASDAQ:TSLA) and others. But that doesn't mean we can't trace the technicals on AMGN stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAt the end of March, AMGN stock was showing weakness and threatening to break down from a short-term double-top. Fast-forward about two weeks and Amgen stock is above all of its major moving averages. While being rejected by downtrend resistance (black line), shares are hanging just below this mark. Could that set up a breakout?That's what I'm looking for in AMGN stock. A drop down to about $190 would give bulls a chance to initiate a position near the 20-day moving average and uptrend support. Whether the pullback is done here, near $193, or drops to $190, as long as support holds, it could give AMGN stock the energy it needs to push through resistance.On the upside, a push through $196 could eventually ignite Amgen up to $206. Shares put in a double-top at this level in the fourth quarter, so it wouldn't be surprising to see this area act as resistance on AMGN's first try. On the downside, watch for support from the 50-day moving average at $188 -- provided uptrend support does not buoy Amgen.Below that, and a drop into the low-$180s is possible. Valuing Amgen StockAmgen stock is looking better and better on the charts, but that doesn't mean there aren't things to like about its fundamentals.For starters, AMGN stock has a 3% dividend yield. Management gave a ~10% bump in December, following increases of ~15% in each of the last two years ago. While the company has experienced lower growth than the past few years, it's clear management is putting an emphasis on returning capital to investors.There's also the valuation, which stands at less than 14 times this year's earnings. There is a catch, though: While this is a below-market valuation, we have to consider it versus its peers as well as against Amgen's own growth profile. When compared to names like Celgene (NASDAQ:CELG), Bristol-Myers Squibb (NYSE:BMY) (who are in M&A discussions) and Gilead (NASDAQ:GILD), Amgen stock is expensive.These stocks trade at roughly 10 times earnings or less, so, at 13.7 times this year's earnings, Amgen looks less attractive. It would help if it had better growth, too. Analysts expect revenue to decline almost 4% this year and for earnings to fall about 2% year over year. That said, consensus expectations do call for a rebound in both metrics in 2020 while AMGN could always top expectations this year. After all, it has beat -- rather impressively, I might add -- top- and bottom-line expectations in each of the past four quarters. * 10 Stocks That Are Screaming Buys Right Now One last note, AMGN stock is actually trading at a discount compared to its five-year average valuation -- and that's not just the price-to-earnings ratio either. Amgen isn't perfect, but if shares are going to break out this year, I don't expect the valuation to inhibit that move.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post Why Amgen Stock Could Break Out to New Highs appeared first on InvestorPlace.
Aiming to generate fresh data to run through its machine learning system, a startup is embarking on a three-year collaboration with one of biotech's biggest players in the fatty liver disease known as NASH.
Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments. The firm - launched last year with investments from Alphabet Inc's Verily and GV among others - uses machine learning to help discover and develop drug candidates. The partnership comes two months after Gilead's experimental NASH drug selonsertib failed to meet its main goal in a late-stage study.
Gilead Sciences Inc. (GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Under the terms of the three-year collaboration, insitro’s proprietary platform will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease. The insitro Human (ISH) platform applies machine learning, human genetics and functional genomics to generate and optimize unique in vitro models and drive therapeutic discovery and development.